Features and evaluation of mucormycosis in COVID-19 patients from two referral hospitals in Iran
July 24, 2024Isolated tracheal mucormycosis in diabetes mellitus and bronchoscopic management
July 24, 2024Dear Editor,
A large number of mucormycosis cases were reported in India following the second wave of COVID-19.[1] However, data on the imaging appearance of COVID-19-associated pulmonary mucormycosis (CAPM) are limited.[2] A few published case reports on CAPM and a systematic literature review suggested cavity and consolidation as the most common finding.[3-6] The primary objective of the current study was to describe the computed tomography (CT) thorax findings of CAPM at diagnosis. The secondary objectives were to compare the CT findings of (1) CAPM in patients with diabetes mellitus (DM) and those with no known traditional risk factors, and (2) survivors and non-survivors with CAPM.
The MuCovi-2 study was a multicentre retrospective study conducted across 25 centres in India between 1 January 2021 and 30 June 2021. Data on COVID-19-associated mucormycosis (microbiologically or pathologically confirmed) cases and age-matched controls were collected in the original study.[7] COVID-19 was diagnosed by detecting SARS-CoV2 infection in nasopharyngeal or throat swabs by rapid antigen testing or reverse transcriptase polymerase chain reaction. (see more)
Muthu V, Agarwal R, Rudramurthy SM, et al. Lung India. 2024 May 1;41(3):221-224. doi: 10.4103/lungindia.lungindia_19_24